Upload
duongkien
View
220
Download
0
Embed Size (px)
Citation preview
New c-Src targets revealed by chemical rescue and proteomics
1
Identification of Targets of c-Src Tyrosine Kinase by Chemical Complementation and
Phosphoproteomics
Isabel Martinez-Ferrando1, Raghothama Chaerkady2,4, Jun Zhong2, Henrik Molina2,5, Harrys
Kishore2,4, Katie Herbst-Robinson1,6, Beverley M. Dancy1, Vikram Katju2,4,7, Ron Bose1,8, Jin
Zhang1, Akhilesh Pandey2,3, and Philip A Cole1,*
1Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine.
Baltimore, MD, USA, 2McKusick-Nathans Institute of Genetic Medicine and Department of
Biological Chemistry, Johns Hopkins School of Medicine. Baltimore, MD, USA, 3Pathology and
Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA, 4Institute of
Bioinformatics, International Technology Park, Bangalore, India, 5Present address: Rockefeller
University Proteomics Research Center. The Rockefeller University, New York, NY, USA,
6Present address: Institute on Aging, University of Pennsylvania, Philadelphia, PA, USA,
7Present address: M.D. Anderson Cancer Center. The University of Texas, Houston, TX, USA,
8Present address: Division of Oncology, Department of Medicine. Washington University School
of Medicine. St Louis, MO, USA
*Corresponding author: Department of Pharmacology and Molecular Sciences, Johns Hopkins
School of Medicine, 725 North Wolfe Street, Baltimore, MD, 21205, USA. Tel.: +1 410 614
8849; Fax: +1 410 614 7717; E-mail: [email protected]
MCP Papers in Press. Published on April 12, 2012 as Manuscript M111.015750
Copyright 2012 by The American Society for Biochemistry and Molecular Biology, Inc.
New c-Src targets revealed by chemical rescue and proteomics
2
Abbreviations
FAK, focal adhesion kinase; PTM, post-translational modifications; LTQ- Orbitrap Velos, linear
ion trap orbitrap Velos mass spectrometer; RapGEF1 (C3G), Rap guanine exchange factor;
SILAC, stable isotope labeling of amino acids in cell culture; SYF/MEFs, Src-, Yes-, and Fyn-
knock out mouse embryonic fibroblasts.
New c-Src targets revealed by chemical rescue and proteomics
3
Summary
The cellular proto-oncogene c-Src is a non-receptor tyrosine kinase involved in cell growth and
cytoskeletal regulation. Despite being dysregulated in a variety of human cancers, its precise
functions are not fully understood. Identification of c-Src’s substrates remains a major challenge,
as there is no simple way to directly stimulate its activity. Here we combine the chemical rescue
of mutant c-Src and global quantitative phosphoproteomics to obtain the first high-resolution
snapshot of the range of tyrosine phosphorylation events that occur in the cell immediately after
specific c-Src stimulation. After enrichment by anti-phosphotyrosine antibodies, we identified 29
potential novel c-Src substrate proteins. Tyrosine phosphopeptide mapping allowed the
identification of 382 non-redundant tyrosine phosphopeptides on 213 phosphoproteins. SILAC-
based quantitation allowed the detection of 97 non-redundant tyrosine phosphopeptides whose
level of phosphorylation is increased by c-Src. A large number of previously uncharacterized c-
Src putative protein targets and phosphorylation sites are presented here, a majority of which
play key roles in signaling and cytoskeletal networks, particularly in cell adhesion. Integrin
signaling and focal adhesion kinase (FAK) signaling pathway are two of the most altered
pathways upon c-Src activation through chemical rescue. In this context, our study revealed the
temporal connection between c-Src activation and the GTPase Rap1, known to stimulate
integrin-dependent adhesion. Chemical rescue of c-Src provided a tool to dissect the
spatiotemporal mechanism of activation of the Rap1 guanine exchange factor, C3G, one of the
identified potential c-Src substrates that plays a role in focal adhesion signaling. In addition to
unveiling the role of c-Src in the cell and, specifically, in the Crk-C3G-Rap1 pathway, these
New c-Src targets revealed by chemical rescue and proteomics
4
results exemplify a strategy for obtaining a comprehensive understanding of the functions of
non-receptor tyrosine kinases with high specificity and kinetic resolution.
New c-Src targets revealed by chemical rescue and proteomics
5
INTRODUCTION
The discovery of c-Src (cellular, wild-type Src) as the proto-oncogene of v-Src (viral,
mutant Src) has led to persistent interest in this non-receptor protein tyrosine kinase in studies of
cell signaling. It is now known that c-Src is involved in regulating cellular growth, adhesion,
motility and invasion. c-Src is frequently overexpressed in human cancer, such as
gastrointestinal, breast, ovarian, and other cancers (1), and it is considered a drug target. In spite
of its linkage to disease and breadth of functions, c-Src’s specific roles in signaling are still not
fully understood.
A variety of biochemical and cellular approaches have been used to identify direct and
indirect tyrosine phosphorylated substrates of Src: many of these cellular substrate identification
studies have used the hyperactive, dysregulated form of Src, v-Src (2, 3), which lacks normal
downregulation by C-terminal phosphorylation on Tyr 527, or constitutively active Src mutants
(for example, Y527F) (4,5). However, v-Src forms are rarely found in human cells, even in
cancer (6). Instead, it would be informative to pursue these studies focusing on the cellular
proto-oncogene c-Src.
Analyzing cellular protein tyrosine phosphorylation targets of c-Src using a proteomics
strategy would require an approach that can directly and specifically monitor c-Src kinase action
rather than previously used indirect methods, such as growth factors activating growth factor
receptor tyrosine kinases that indirectly stimulate c-Src (7). Related work has been done in this
regard combining chemical genetics of kinases (8-10) and proteomics (11). For our goals, the
challenge was to achieve specific and rapid activation of c-Src in living cells that will allow
New c-Src targets revealed by chemical rescue and proteomics
6
identification of substrates temporarily close to c-Src activation. An attractive strategy to pursue
these objectives involves chemical rescue of mutant c-Src tyrosine kinase.
It has previously been shown that mutation of a highly conserved Arg (390 in c-Src) in
protein tyrosine kinases (PTKs) results in a dramatic reduction in catalytic activity (200-5000-
fold), presumably because of the loss of a key hydrogen bonding side chain responsible for
orienting the substrate tyrosine phenol for phosphoryl transfer (12-14). A variety of di- and
triamino compounds added to the enzyme reaction buffer have been shown to complement this
defective kinase activity, the most efficient being imidazole (12-14). Structural and pH studies
suggest that positively charged imidazolium occupies the unnatural cavity found in R/A mutant
PTKs and serves to rescue the catalytic function without significantly affecting c-Src substrate
selectivity (14) (Figure 1A). Indeed, in the case of the Src kinase domain, treatment of R390A v-
Src with imidazole stimulates catalytic activity by about 100-fold to within 40% of the wild-type
level and appears to have native substrate specificity and regulation in vitro (3). It was also
shown that imidazole, a relatively non-toxic small molecule, could rescue R390A v-Src in cell
culture (3).
By combining the specific and controlled activation of c-Src by chemical rescue with the
ability of quantitative SILAC phosphoproteomics to provide the phosphorylation fingerprint of
cells in different conditions, we have identified a number of potential novel c-Src targets and
discuss the potential ramifications of these phosphorylation events in cell signaling. Chemical
rescue has also served as a powerful tool to dissect the mechanism of activation of one of the
identified targets (C3G) in a spatiotemporal manner.
New c-Src targets revealed by chemical rescue and proteomics
7
Experimental Procedures
Cell Culture and SILAC
Src-, Yes-, and Fyn- triple knockout mouse embryonic fibroblast cells (hereafter referred
to as SYF cells) (ATCC) stably transfected with either R390A c-Src or D388N c-Src constructs
as previously described (3) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% (v/v) qualified fetal bovine serum (FBS) (Invitrogen), 1% (v/v) of
penicillin-streptomycin-glutamine (PSG) (Invitrogen) and 300 µg/ml of Hygromycin B (Roche)
and incubated at 37ºC in the presence of 5% CO2. R390A c-Src SYF MEF cells (hereafter
referred to as R390A/ SYF MEF cells) were adapted to the SILAC media. A detailed protocol
for SILAC media preparation can be obtained from http://www.silac.org. Arginine- and lysine-
free DMEM media were bought from Athena Enzyme Systems. c-Src R390A stably transfected
SYF cells were cultured in Arg-/ Lys- free DMEM media supplemented with light (12C6 Arg/
12C6 Lys) amino acids from Sigma or heavy (13C6 Arg/ 13C6 Lys) amino acids from Cambridge
Isotope Laboratories, Inc. Both media contained 10% qualified FBS (Invitrogen), 1% PSG
(Invitrogen) and 300 µg/ml of Hygromycin B (Roche). The cells were adapted to the SILAC
medium by growing them in these media for at least 5 replication cycles, as described earlier
(15). When starved, cells were cultured in the same medium lacking serum. The p-Tyr
proteomes were assessed from cells actively growing and motile at ~75% confluency.
Untransfected SYF cells and wt MEFs were grown as above without hygromycin
treatment.
New c-Src targets revealed by chemical rescue and proteomics
8
Cell treatment and peptide preparation
Thirty 150mm diameter plates of R390A/SYF cells (per condition) were serum-starved
for 16 hours. Cells grown in 13C6 Arg/ 13C6 Lys- containing media (heavy media) were treated
with 10 mM imidazole, pH 7.5 for 5 minutes, whereas cells grown in 12C6 Arg/ 12C6 Lys-
containing media (light media) were left unstimulated and used as a control. Both cells sets were
then washed once with ice cold PBS (Invitrogen) and immediately lysed in Urea lysis buffer (20
mM HEPES pH 8.0, 9 M urea, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1
mM ß-glycerophosphate) by 3 bursts of ultrasonication (Duty cycle 40%, output control at 4, on
Sonifier 250, Branson) at 4 °C. After sonication, the lysate was cleared by centrifugation at
20,000 x g for 15 min and the supernatant collected. Three biological replicates were conducted.
Protein concentrations were calculated by Bradford (Supplementary Figure 1A). As a further
loading control equal amount of lysates (50 µg) were mixed with SDS loading buffer and boiled
at 95ºC for 5 minutes, analyzed by SDS-PAGE and stained with Colloidal Coomasie
(Supplementary Figure 1A).
Tyrosine phosphopeptide enrichment
Phosphotyrosine protein profile with and without imidazole treatment was analyzed by
immunoaffinity purification of phosphoproteins with 4G10 anti-phosphotyrosine antibody
followed by western blot using 4G10 anti-phosphotyrosine antibody (Supplementary Figure 1B).
“Heavy” and “Light” lysates were mixed in protein concentration ratios 1:1. As a result, a total
New c-Src targets revealed by chemical rescue and proteomics
9
amount of 35 mg (first biological replicate), 50 mg (second biological replicate) and 52 (third
biological replicate) were generated for phosphotyrosine peptide profiling. Two of the 3
biological replicates had two technical replicates with respect to LC-MS/MS. LC-MS analysis of
sample aliquots were performed to observe the equal mixing of heavy and light cell lysate
proteins using a Micromass quadrupole time-of-flight mass spectrometer (QTOF) Ultima API
(Waters) (Supplemental Figure 1C).
Proteins were reduced with DTT at a final concentration of 4.5 mM and alkylated with 10
mM iodoacetamide. Lysates were diluted in 20 mM HEPES pH 8.0 to a final concentration of 2
M urea. 1/100 vol/vol of 1mg/ml trypsin- TPCK (Worthington Biochemical Corporation) was
added to the diluted protein extracts and digestion was performed overnight at 25 ºC. The lysates
were analyzed before and after digestion as a control (Supplementary Figure 1D) using SDS-
PAGE and colloidal Coomassie staining.
The protein digests were acidified with trifluoroacetic acid (TFA) at a final concentration
of 1%. The acidified peptide solutions were centrifuged at 1,800 x g for 5 minutes to remove the
precipitate. The clear supernatants were loaded onto Sep-Pak C18 cartridges (Waters, cat no:
WAT051910) previously wetted with 100% acetonitrile and equilibrated with 0.1% TFA. The
cartridges were then washed with 0.1% TFA and acidified peptide samples were passed through
cartridge by gravity. The peptides were eluted by 40% acetonitrile (ACN) /0.1% TFA. The
eluted peptide solutions were lyophilized to remove residual TFA completely.
Immunoaffinity purification of tyrosine phosphopeptides
New c-Src targets revealed by chemical rescue and proteomics
10
Anti phospho- tyrosine antibody based immunoaffinity purification (IAP) of
phosphopeptides was carried out according to manufacturer protocol (16). Lyophilized peptides
from each of the fractions (3 biological replicates, 2 technical replicates) were dissolved with 1.4
ml of IAP buffer (50 mM MOPS pH 7.2, 10 mM sodium phosphate, 50 mM NaCl) aided by
shaking and brief sonication. Solution was cleared by centrifugation for 5 minutes at 1,800 x g.
The phosphotyrosine antibody-linked beads (Cell Signaling Technology) (250 µg in 40 µl) were
washed with IAP buffer (1.4 ml IAP buffer, mix by invert 5 times) once and incubated with the
cleared peptide solution for 30 minutes at 4ºC with gentle shaking. The phosphopeptide bound
antibody beads were washed twice with IAP buffer and twice with water at 4ºC.
Phosphopeptides were eluted from the beads by incubation with 55 µl of 0.15% TFA at 20-25ºC
for 10 minutes followed by second extraction with 45 µl of 0.15% TFA.
The eluted phosphopeptides were desalted using Stage-Tip protocol described previously
(17). The peptide eluate was then dried at 25ºC in Speed-Vac for mass spectrometry analysis.
LC-MS/MS analysis of tyrosine phosphorylated peptides
LC-MS/MS analysis of phosphopeptides enriched by IAP was carried out using a
reversed-phase liquid chromatography system interfaced with Fourier transform LTQ-Orbitrap
Velos mass spectrometer (FT-MS) on a “high-high” mode (both MS and MS/MS analyses were
carried out in FT-MS mode) (Thermo Scientific). The reversed phase setup consisted of a trap
column (2 cm × 75 µm, Magic C18 AQ material 5µm, 100 Å) and an analytical column (10 cm ×
75 µm, Magic C18 AQ material 5 µm, 100 Å). After concentration and desalting on the pre-
column, peptides were eluted and separated on the analytical column using a gradient increasing
New c-Src targets revealed by chemical rescue and proteomics
11
from 100% solvent A/ 0% solvent B (Solvent A: 0.1% formic acid, solvent B: 100% acetonitrile,
0.1% formic acid) to 40% buffer A/60% solvent B in 135 min. Each survey scan involved
precursor scan from 350-1600 m/z at 60,000 resolution and data dependent higher collision
dissociation (HCD) MS/MS scans for 10 most intense precursor ions at 7,500 resolution.
Normalized collision energy was 35% and monoisotopic precursor selection enabled with
isolation width of 1.9 m/z.
Data analysis
The acquired mass spectra were processed and searched using MaxQuant (version 1.2)
(18), Mascot (19) and Sequest (20) since these algorithms are complementary which can broaden
protein and site identification (21). Searches using the latter two were submitted via Proteome
Discoverer (version 1.3, Thermo Scientific), which allowed merging search results and
quantitating the SILAC pairs. It should be noted that although there was a large difference between
Mascot and Proteome Discoverer for redundant peptides (about 10-fold), perhaps related to initial
curation stringency, this difference becomes minor when comparing non-redundant peptides (<2-
fold). We believe that the similarity in non-redundant peptides is the more important comparison.
All MS/MS spectra were searched against the RefSeq mouse protein database (v. 40, containing
31,183 entries). For all searches, two missed cleavages were allowed; carbamidomethylation of
cysteines were set as a fixed modification. N-terminal acetylation, deamidation of asparagine and
glutamine, oxidation at methionine, phosphorylation at serine, threonine and tyrosine together
with the ‘heavy’ lysine and arginine were used as variable modifications.
Monoisotopic peptide tolerance was set to 10 p.p.m. for precursors and 0.05 mDa for
MS/MS fragment ions. Peptides fulfilling a FDR of 1% were reported. Peptides with inconsistent
New c-Src targets revealed by chemical rescue and proteomics
12
ratios or unusual high ratios altered were manually checked. We established a threshold H/L
ratio value of 1.2. Phosphopeptides showing an average (from the three biological replicates)
SILAC ratio of 1.2 or above from Proteome Discoverer, MaxQuant, or both were considered
upregulated upon c-Src rescue. Four filtering criteria were used to obtain a high-confidence data
set of quantified phosphotyrosine peptidesIf manual validation was satisfactory and showed a
rounded SILAC ratio of 1.2 or above, the peptides were included on the list. A detailed flow-
chart of the process is included in Supplementary Figure 2.
Tyrosine phosphoprotein enrichment and quantitative analysis
SYF/MEF cells stably transfected with R390A c-Src were cultured, isotopically labeled and
treated as described above. Immunoaffinity purification of tyrosine-phosphorylated proteins was
carried out as described previously (3). The enriched tyrosine-phosphorylated proteins were
subjected to in-gel digestion as described previously (3). The resulting tryptic peptides were
analyzed by reversed phase LC-MS/MS using a quadrupole-time-of-flight mass spectrometer
(QSTAR Pulsar, MDS Sciex, Concord, Ontario, Canada) coupled to an 1100 series CapLC
(Agilent, Santa Clara, CA). Acquired data were queried against the RefSeq mouse protein
database (v.26, containing 20311 entries) using MASCOT v.2.2.2 (Matrixscience, London,
England) and quantitated using MSQuant v1.4.3a39 (http://msquant.sourceforge.net). Mass
tolerance of 1.1 Dalton was used for precursors and 0.1 Da for fragment ions. Fixed modification
with carbamidomethylation of cysteines was set while N-terminal acetylation, deamidation of
asparagine and glutamine, oxidation at methionine, phosphorylation at serine, threonine and
New c-Src targets revealed by chemical rescue and proteomics
13
tyrosine together with ‘heavy’ lysine and arginine was set as variable modifications. Quantitation
was performed using MSQuant as described on http//msquant.sourceforge.net.
Network Modeling and Literature Curation
Phosphosite (http://phosphosite.org), Human Protein Research Database (HPRD) (22)
(http://hprd.org), and literature curation were used to differentiate previously unidentified and
known substrates from the list of proteins showing increased phosphorylation upon c-Src rescue.
Phosphosite was used to establish the protein type classification of the detected proteins. The
Ingenuity pathway analysis software (Ingenuity ® Systems, www.ingenuity.com) and literature
curation were used to investigate previously observed connections between c-Src and the protein
of study.
The Ingenuity pathway analysis software was used to perform ontology and canonical pathway
enrichment analysis of the proteins associated with the found tyrosine phosphopeptides
experiencing an increase in their tyrosine phosphorylation level upon c-Src rescue. The online
web tool DAVID Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov. (23) and the
Ingenuity pathway analysis software were used to obtain a representation of the role of c-Src on
focal adhesion pathways. The list of proteins corresponding to the peptides identified as
upregulated upon c-Src rescue was uploaded in the DAVID tool, which incorporated the newly
discovered proteins to the to the pathway. The pathway was completed using Ingenuity Systems.
Both the known and the newly discovered potential c-Src phosphorylation sites were
incorporated to the graph manually and validated with Phosphosite and HPRD.
New c-Src targets revealed by chemical rescue and proteomics
14
Immunobloting and Immunoprecipitations
After imidazole treatment cells were washed once with PBS and lysed for 30 min at 4ºC
in RIPA buffer (Tris-HCl 50 mM pH 7.4, Na-deoxycholate 0.25%, NaCl 150 mM, EDTA 1mM,
1% NP-40, Na3VO4 1 mM, NaF 1 mM, PMSF 1 mM), and centrifuged at 13,000 x g at 4ºC. The
supernatants were collected for immunobloting and immunoprecipitation.
For immunobloting the supernatants were mixed with SDS loading buffer and boiled at
95ºC for 5 minutes, analyzed by SDS-PAGE. The proteins were electroblotted into PVDF
membrane (Invitrogen). The membrane was probed with appropriate antibody, followed by
incubation with the correspondent HRP- conjugated secondary antibody. Antibodies were used at
the recommended concentration in the manufacturer´s instructions. Bands were visualized using
SuperSignal West Pico chemiluminescent substrate (Pierce).
For immunoprecipitation, the supernatants were pre-cleared with protein A or G agarose
and subsequently incubated overnight with the antibody at 4ºC. Antibodies were used at the
recommended concentration in the manufacturer’s instructions. Mixtures were treated with
protein A or G agarose and then incubated at 4ºC overnight. The agarose beads were
subsequently washed three times by RIPA buffer, resuspended in SDS loading buffer with β-
Mercaptoethanol and boiled. The eluates were analyzed by SDS-PAGE and Western Blot
analysis.
Antibodies were obtained as follows: PHOSPHOTYROSINE: (4G10) from Upstate
Biotechnology. FAK: 06-543 (Fak IP and WB) from Upstate Biotechnology. PAXILLIN: 05-417
(Paxillin IP and WB) from Millipore. VIMENTIN: ab8978 (Vimentin IP), ab58462 (Vimentin
New c-Src targets revealed by chemical rescue and proteomics
15
WB) from Abcam, Inc. C3G: sc869 (C3G IP and WB) from Santa Cruz Biotechnology. TENSIN:
sc28542 (Tensin IP and WB) from Santa Cruz Biotechnology. MATRIN: sc55724 (Matrin IP and
WB) from Santa Cruz Biotechnology. NUCLEOPHOSMIN: ab10530 (Nucleophosmin IP and WB)
from Abcam. GSK3β: CST9315 (GSK3β IP) from Cell Signaling Technology, sc81462 (GSK3β
WB) from Santa Cruz Biotechnology, CST9315 (GSK3β WB) from Cell Signaling Technology.
C3G sc-15359 (C3G WB) from Santa Cruz Biotechnology, pTyr514-C3G sc-32612 (pTyr514-
C3G WB) from Santa Cruz Biotechnology. C3G IP/ CRK WB: sc-15359 (C3G IP) from Santa
Cruz Biotechnology, 610035BD (Crk WB) from BD Transduction Laboratories. CRK (PTYR221)
WB: ab76227 (WB) from Abcam, Inc. All Western blots were performed at least twice and
results shown are representative. It should be noted that baseline values between rescuable and
non-rescuable cells may not be the same due to subtle alterations in the cell passage number,
growth conditions, or western blot conditions (such as exposure time).
Immunofluorescence and Confocal Microscopy
Cells were seeded and grown in 8-well glass microscopy slides (Lab-Tek). Cells were
processed for immunofluorescence staining in the following way: After imidazole treatment (10
mM, 5 minutes), cells were washed once with ice cold PBS. Cells were fixed with 4%
formaldehyde (Tousimis Reserch Corporation) for 1 h at 4°C followed by washing with 10mM
Glycine in PBS. Permeabilization was performed with 0.2% (v/v) of Triton X100 in PBS for 5
min at room temperature. After washing with PBS, cells were incubated in blocking solution
(10mg/ml BSA in PBS).
New c-Src targets revealed by chemical rescue and proteomics
16
The primary antibodies used were rabbit polyclonal antibody against C3G (SC-13359
from Santa Cruz Biotechnology) and rabbit polyclonal antibody against pTyr514-C3G (SC-
12926 R from Santa Cruz). The secondary antibodies used were Alexa-Fluor 555 goat anti-rabbit
(A-21430 from Invitrogen) and Alexa-Fluor 488 chicken anti-rabbit (A-21441 from Invitrogen)
respectively. The slides were mounted with ProLong® Gold Antifade Reagent (With DAPI)
from Invitrogen. Samples were acquired with the Zeiss Meta Confocal Laser Scanning
Microscope System, utilizing AIM software version 4.0. An Argon laser exciting at 488nm and
a red HeNe at 561 nm wavelengths were used to obtain optical sections. Narrow band emission
filters (nm) were utilized to eliminate channel cross-talk and a 1.0 µm confocal aperture was
used to obtain z-plane sections. Slides were imaged with 40x and 100x oil immersion Plan
Apochromat objective lens (N.A. 1.4) through a Zeiss Axiovert inverted microscope. For
quantification, at least 40 cells were counted for each condition and scored according to whether
or not they had peripheral staining. Percent of cells with a peripheral staining was calculated for
each 40x window. Averages and standard errors are shown and statistical analysis was done
using the Student’s t test.
FRET Microscopy
R390A and D388N c-Src SYF MEF cells were plated to glass bottom dishes (MatTech
Corp.) and transiently transfected with 2µg Raichu-Rap1 (24) reporter using lipofectamine
(Invitrogen). The cells were starved for 16 hours. After 15 h cells were washed once and media
was replaced with Hanks Balanced Salt Solution (HBSS). The dish was loaded onto the stage of
an inverted Zeiss Axiovert 200M microscope controlled by METAFLUOR software (Universal
New c-Src targets revealed by chemical rescue and proteomics
17
Imaging, Downingtown, PA). Dual emission ratio imaging was performed using a 420DF20
excitation filter and a 450DRLP dichroic mirror and appropriate emission filters, 475DF40 for
CFP and 535DF25 for YFP. Images were captured with a MicroMAX BFT512 CCD camera
(Roper Scientific, Trenton, NJ). Baseline values were captured every 30 seconds for 2 minutes.
Cells were treated with 10mM imidazole at time zero and imaged for an additional 15-20
minutes. Images were quantified using the Metafluor software. Regions of interest were selected
and average intensities of the pixels in each region for each channel were quantified. FRET ratios
were calculated by dividing the yellow emission over the cyan emission at each time point.
New c-Src targets revealed by chemical rescue and proteomics
18
RESULTS
c-Src chemical rescue
The chemical rescue of mutant v-Src provides precise temporal control of its intracellular
kinase activity (3). In order to test whether we could observe similar results with cellular c-Src,
we used SYF (Src-, Yes-, and Fyn-triple knockout) MEF cells stably transfected with R390A c-
Src (R390A/SYF cells). The triple knockout reduces the background from endogenous c-Src, as
well as two other members of the Src kinase family, Yes and Fyn (25). We observed that
treatment of SYF MEF cells stably transfected with R390A c-Src using a range of 2.5-5 minutes
and 2-10 mM imidazole induced a time-dependent, dose-dependent increase in range and
intensity of tyrosine-phosphorylated protein bands as visualized by western blot analysis of
whole cell lysate with 4G10 anti-phosphotyrosine antibody (Supplementary Figure 3 and Figure
1). The imidazole-insensitive inactive c-Src mutant D388N/SYF cells were used as a negative
control since they express an inactive Src kinase at similar levels (3) and should be most similar
to the untreated R390A/SYF cells. In prior studies (3), it was shown that D388N/SYF cells are
unresponsive to imidazole. We confirmed here that D388N/SYF cells showed no such change in
protein tyrosine phosphorylation with 10 mM imidazole and 5 minute treatment, compared with
the imidazole-sensitive R390A/SYF c-Src mutant (Figure 1B), suggesting that the imidazole
effect was specific. The modest baseline western blot differences (minus imidazole) between
D388N/SYF and R390A/SYF cells are not consistent (see ref. 3) and likely represent subtle
differences in passage numbers and clonal populations. To further ensure that imidazole had no
New c-Src targets revealed by chemical rescue and proteomics
19
major effects on cellular tyrosine phosphorylation outside of chemical rescue under these
conditions, we investigated its effect on SYF and WT MEF cells. As shown in Supplementary
Figure 4, there were no appreciable changes in anti-pTyr western blots of cell lysates treated with
or without imidazole.
After a series of optimization experiments, we selected 10 mM imidazole and 5 minutes
exposure as the optimal conditions for c-Src rescue in our R390A/SYF cells. Since our goal was
to identify the c-Src-induced phosphoproteome, we combined c-Src chemical rescue with mass
spectrometry and stable isotope labeling with amino acids in cell culture (SILAC) (Figure 2)
(26). R390A c-Src-expressing SYF cells were labeled with either 13C6-Arg/ 13C6-Lys (heavy) or
12C6-Arg/ 12C6-Lys (light). “Heavy” cells were treated with 10 mM imidazole for 5 minutes and
“light” cells were left untreated (control) to distinguish the c-Src induced tyrosine
phosphorylation events from the background of steady-state tyrosine phosphorylated proteins in
the cell.
Phosphoprotein identification and quantitation
As an initial approach to test the combined advantages of chemical rescue and a
proteomics analysis, protein enrichment was performed by immunoprecipitation with anti-
phosphotyrosine antibody (Figure 2A). The phosphotyrosine proteins were analyzed by tandem
mass spectrometry. The complete list of identified proteins is shown in Supplementary Table 1,
and a summary of fold change in phosphorylation upon c-Src chemical rescue for all proteins is
included in Figure 3A. It can be surmised that the 35 proteins showing SILAC ratios greater
than or equal to 1.2 are targets of c-Src-mediated tyrosine phosphorylation and in fact, at least six
New c-Src targets revealed by chemical rescue and proteomics
20
of these are previously documented c-Src substrates. While it is tempting to infer that larger
SILAC ratios suggest greater confidence in undergoing c-Src-mediated phosphorylation, this is
not necessarily the case. For example, the well-established c-Src substrate focal adhesion kinase
(FAK) showed a modest ratio of 1.2. The proteins with a SILAC ratio of 1.2 or above were
classified into five protein type classes (Figure 3B) according to the Phosphosite bioinformatics
resource (www.phosphosite.org) (27). Interestingly, the most represented cellular functions were
signaling pathways (37%) – with proteins such as nucleophosmin, G3BP-2, Map kinase, C3G,
and cullin 5 – and adhesion and cytoskeleton (26%) – vimentin, tensin 1, matrin 3, plectin 1,
fibronectin 1, and myosin X. A subset of the 29 potentially novel c-Src targets have been
functionally linked to c-Src signaling pathways such as vimentin (28) and nucleophosmin (29),
although the experiments here show unique evidence that they are closely temporally linked to c-
Src kinase action.
Confirmation of c-Src targets by immunoprecipitation-western blot analysis
We thus selected a set of identified proteins to confirm chemical rescue-induced tyrosine
phosphorylation using an immunoprecipitation-western blot approach in c-Src R390A/SYF cells.
The D388N/SYF cells serve as negative controls. As described previously, paxillin and Fak are
well-established c-Src substrates and therefore served as positive controls, which showed
imidazole-enhanced signal intensity when blotting with 4G10 anti-phosphotyrosine antibody
after immunoprecipitation (Supplementary Figure 5).
We showed that C3G, vimentin, tensin 1, matrin 3, nucleophosmin, and Gsk-3ß could be
efficiently immunoprecipitated from SYF cells (Figure 4). Analysis of these immunoprecipitated
New c-Src targets revealed by chemical rescue and proteomics
21
proteins with anti-phosphotyrosine antibody showed an increase in the phosphorylation of each
of these proteins from R390A/SYF but not D388N/SYF cells when treated with 10 mM
imidazole for 5 minutes. The loading controls were performed by immunoprecipitation with a
specific protein antibody followed by blotting with an antibody against the same protein. These
data suggest that tyrosine phosphorylation of each of these proteins depends on c-Src kinase
activity, with a close temporal connection to c-Src rescue.
Phosphosite mapping by chemical rescue of mutant c-Src
Given the success in our preliminary attempt to combine c-Src chemical rescue and
phosphoproteomics, we decided to perform an extensive phosphopeptide mapping and
quantitation of phosphorylation changes in the cell upon c-Src rescue. The protocol described
above for quantitative analysis of protein tyrosine phosphorylation was modified such that
trypsin proteolysis of extracted proteins was performed prior to affinity based enrichment with
anti-phosphotyrosine antibody (Figure 2B). In addition, three biological replicates and two
technical replicates were performed (Supplementary Figure 2) and analyzed using high
resolution, high accuracy mass spectrometry (30). Mascot and Sequest led us to the
identification of an initial list of redundant tyrosine phosphopeptides (Supplementary Table A).
That translated into a list of 335 non-redundant peptide sequences (corresponding to 205
proteins). In parallel, the quantitative proteomics software MaxQuant led us to the identification
of an initial list of redundant tyrosine phosphopeptide spectrum matches (Supplementary Table
B) that translated into a list of 216 non-redundant tyrosine phosphopeptides (corresponding to
New c-Src targets revealed by chemical rescue and proteomics
22
147 proteins). We assembled a proteome comprising 382 non-redundant peptide sequences,
corresponding to 334 tyrosine phosphorylation sites on 213 proteins (Supplementary Table 2).
We set a threshold value of 1.2-fold for SILAC ratio (heavy vs. light ≥ 1.2) to filter for
tyrosine-containing peptides with increased phosphorylation level upon c-Src rescue. A high-
confidence data set of quantified phosphotyrosine peptides was obtained through a four filtering
criteria described in the Experimental Procedures section. After manual validation we obtained a
list of 97 non-redundant peptide sequences, corresponding to 85 tyrosine phosphorylation sites
(corresponding to 52 proteins), as upregulated in response to chemical rescue of c-Src,
suggesting that they may be c-Src targets. A complete list of the mapped proteins with sites
showing an increased phosphorylation level upon c-Src chemical rescue is provided in
(Supplementary Table 3).
Several of these sites were identified in proteins that also showed an increased
phosphorylation level at the protein level (such as C3G, tensin 1, Pard3 and Lpp), adding further
confidence to their significance. The proteins containing the tyrosine residues which showed an
increased phosphorylation level upon c-Src rescue can be classified into several categories
(Figure 5) including actin modeling, adaptor/scaffold, adhesion, guanine exchange factors/
GTPase-activating proteins, non-receptor protein kinases, phosphatases, cell polarity, and
receptor tyrosine kinases and a group of proteins with diverse functionalities.
We analyzed the c-Src upregulated phosphoproteome with the Ingenuity Pathways
Knowledge Software (Ingenuity ® Systems, http://www.ingenuity.com) and looked for
enrichment of both ontology (Figure 6A) and canonical pathways (Figure 6B). Not surprisingly
two of the most enriched pathways are the integrin and the focal adhesion signaling pathways.
The cellular movement category appears to be the functionality that is especially impacted upon
New c-Src targets revealed by chemical rescue and proteomics
23
c-Src activation. Both integrin-mediated focal adhesion formation, and adherens junction
formation and focal adhesion disassembly (turnover) mediate cellular motility and are involved
in cancer invasiveness and progression (1). A large number of the identified sites are involved in
cell adhesion, particularly in focal adhesion regulation, where c-Src plays key role (31, 32). In
this context, several phosphosites have been found in potential novel c-Src substrates. Also,
novel sites in well-established c-Src substrates have shown an increased tyrosine
phosphorylation level (Figure 7).
Although the tyrosine phosphoproteome provided here is not likely to include the entire
c-Src phosphoproteome, it is the first snapshot of the tyrosine phosphorylation events that take
place immediately (5 minutes) after c-Src specific activation and the first one that has been
obtained through high-resolution, high accuracy mass spectrometry.
The role of c-Src in C3G-mediated mechanism of Rap1 activation
We next explored the potential of chemical rescue as a tool to explore the biological
significance of the phosphorylation of one of the detected proteins, C3G, in response to c-Src
chemical rescue. C3G was identified in both proteomic approaches (phosphoprotein enrichment
and phosphopeptide enrichment) and was validated through immunoprecipitation and western
blot as mentioned above. Furthermore, C3G has shown to play a role in focal adhesion signaling
(33) as can be shown in Figure 7. C3G is a guanine nucleotide exchange factor for the small
Ras-related G-proteins Rap1, Rap2, and R-Ras (34-37). It is known that C3G is phosphorylated
on Tyr514 and this PTM has been shown to be critical for the activation of C3G (38). Previous
New c-Src targets revealed by chemical rescue and proteomics
24
studies have suggested possible roles of Hck, Jak2, and c-Src kinases in Tyr514 phosphorylation
(38-40). In this study, we have observed that imidazole treatment of R390A/SYF cells but not
D388N/SYF cells led to an increase in Tyr514 phosphorylation of C3G as observed by western
blot with an anti-pTyr514 antibody (Figure 8A). This increase was observed within 1 minute of
imidazole exposure supporting the possibility that C3G is a direct substrate of c-Src. Additional
tyrosine phosphorylation sites mat account for the large overall increase in C3G overall tyrosine
phosphorylation level (Figure 4), such as the newly identified site, Tyr 571, which shows an
approximate 3-fold for SILAC ratio upon c-Src rescue.
In addition to C3G phosphorylation, it has been shown that C3G activation occurs
through membrane recruitment (39, 42-44). Redistribution of C3G within the cell, probably to
sites where Rap1 is located, occurs through binding of C3G proline-rich regions to the SH3
domain of the adaptor protein Crk, whose SH2 domains bind to phosphorylated sites resulting
from activated receptors (40, 41, 45). In order to further dissect this signaling process, we
explored the potential changes in protein-protein interactions between C3G and Crk as a result of
c-Src chemical rescue. After imidazole treatment of R390A/SYF cells, C3G protein was pulled
down and co-immunoprecipitated Crk was detected by Western blot (Figure 8B). We observed
that increased Crk was pulled down by C3G immunoprecipitation only 1 minute after rescue of
R390A/SYF but not D388N/SYF cells. The increased binding of C3G and Crk was maintained
until 5 minutes, when it experienced a decrease. We could therefore conclude that c-Src
activation leads to an immediate increase in binding between C3G and Crk.
In order to gain a better understanding of the dynamics of the Crk-C3G interaction, we
explored the possible cause of the observed decrease in binding after 5 minutes upon c-Src
rescue. Crk is negatively regulated when it is phosphorylated on Tyr221, which occurs as a
New c-Src targets revealed by chemical rescue and proteomics
25
result of various types of stimulation (46-48). We examined the phosphorylation level of Tyr221
site with a phosphospecific antibody after chemical rescue at the same time points used to
observe C3G-Crk interaction (Figure 8C). Indeed, phosphorylation of Crk on Tyr221 reaches a
peak at 5 minutes, the same time as when C3G-Crk dissociation is first observed.
To further examine the connections between c-Src and C3G, we explored the subcellular
localization of C3G using immunofluorescence and confocal microscopy after chemical rescue.
As expected, C3G was mainly cytoplasmic at baseline. However, upon imidazole treatment, a
greater concentration was observed at the cell periphery in R390A c-Src expressing SYF cells
(Figure 8D) but this was not observed in D388N c-Src expressing SYF cells (Supplementary
Figure 6). This was detected 1 minute after imidazole treatment and persisted until 5 minutes,
after which it showed a decrease (Figure 8D, Supplementary Figure 6). Cells with peripheral
staining showed both membrane and subcortical localization. Moreover, localization of
pTyr514-C3G before and after c-Src rescue showed a similar trend as C3G, with a peak in
peripheral localization of pTyr514-C3G at 2.5 minutes (Figure 8D, Supplementary Figure 6).
Rap1 is a small G-protein of the Ras family that antagonizes Ras by sequestering their
common target, Raf1, in its inactive form (49-51). It has also been suggested to play an
important role in integrin-mediated cell-adhesion (52). Thus we wanted to examine the effects
of c-Src-mediated activation of C3G on Rap1. We employed the cell-based reporter Raichu-
Rap1 (24), which is designed to undergo a FRET change upon Rap1 activation. As shown in
Figure 8E, imidazole treatment of R390A/SYF cells but not D388N/SYF cells indeed stimulates
Rap1 within 5 minutes primarily at the cell periphery. C3G activation of Rap1 appears therefore
to be controlled by c-Src activation.
New c-Src targets revealed by chemical rescue and proteomics
26
In this way we were able to further elucidate the mechanism of C3G activation following
c-Src chemical rescue in a precise spatiotemporal manner that could have been very difficult to
obtain with traditionally used methods for the study of signal transduction.
Discussion
Previous studies have focused on proteomic analysis on oncogenic viral v-Src (3) or
constitutively active Src mutants (4, 5). In addition, some of these studies have examined
tyrosine phosphorylation patterns several hours or days after Src is expressed, allowing chronic
changes in phosphoproteins to be ascertained. Such analyses are well-suited to identification of
possible biomarkers in v-Src expressing tumors, which appear to be very rare, but likely reflect
many secondary changes in cellular protein levels relating to Src’s well established effects on
growth and gene expression. A recent study focused on cellular c-Src’s kinase action in response
to treatment with SU6656 inhibitors and posterior stimulation with platelet-derived growth factor
(PDGF) (7). Proteomic analysis after the acute activation of tyrosine kinases by ligands such as
growth factors have been particularly informative because they have revealed how a cascade of
signaling is initiated in a temporal fashion, but give rise to indirect information about non-
receptor kinases.
In order to identify temporally direct substrates of the proto-oncogene c-Src, it would be
ideal to use a method to rapidly and specifically switch on c-Src activity in the cell. In contrast
to receptor tyrosine kinases, most non-receptor tyrosine kinases cannot readily controlled in this
fashion. However, the chemical rescue of the R390A c-Src mutant provides a strategy that
perfectly fits this purpose since it provides a rapid, specific and reversible mechanism of c-Src
New c-Src targets revealed by chemical rescue and proteomics
27
activation by the small molecule imidazole, allowing the detection of the immediate effects of
the restored Src activity in cells (3). Prior in vitro studies on the tyrosine kinases Csk, Src, and
Abl have indicated that the imidazole concentration used here (<30 mM) has no effect (<10%)
on wt kinase activity (3, 12,14). Furthermore, previous experiments on chemical rescue of R/A
Csk and Src with imidazole in cell culture have revealed that this chemical rescue approach
recapitulates, without apparent toxic effects, expected tyrosine kinase activities involved in stress
fiber formation, vascular tube formation, cell migration and transformation, and guanylyl cyclase
modulation (3, 12-14, 53, 54). Extensive western blot analysis from an earlier report (3) and
contained in the current study show no evidence of cellular tyrosine phosphorylation mediated
by imidazole in control cell lines. Although we cannot completely rule out that at the level of
mass spectrometric analysis some imidazole effects may be non-specific, we believe that the
accumulated evidence suggests that the chemical rescue approach is a robust technique for
phosphoproteomics.
Combining the power of chemical rescue with proteomics led us to the identification of
28 potential new c-Src protein substrates and 85 tyrosine phosphorylation sites (corresponding to
52 proteins), which showed an increased phosphorylation level upon c-Src rescue. It is
reassuring that several of the putative protein substrates of c-Src that we have uncovered in this
work have been linked to Src in prior studies. We note that 16 of the proteins found here using
c-Src rescue were found among the 140 putative Src kinase targets identified in a combined list
(Supplementary Table 4) of the four prior mass spectrometry phosphoproteomics studies (3-5,7)
reported previously. The lack of greater overlap is likely due in part to the divergent
experimental approaches. It must be cautioned that even chemical rescue cannot unequivocally
assign a protein as a direct kinase substrate of c-Src since the changes in phosphorylation we see
New c-Src targets revealed by chemical rescue and proteomics
28
can result from secondary effects, which can happen within the time frame used in our
observations (5 minutes). Indeed, the class of proteins that show a decrease in tyrosine
phosphorylation likely reflects examples of a secondary phenomenon where a protein tyrosine
phosphatase is activated by phosphorylation. For example, protein tyrosine phosphatases SHP1
and SHP2 are known to be activated by tyrosine phosphorylation and such a mechanism could
contribute to specific dephosphorylation events (55, 56). Nevertheless, in order to define the
characteristics of signaling networks, it is helpful to elucidate the temporal connection among
phosphoprotein changes, even if the protein interactions are indirect.
Activation of c-Src by growth factors or activating mutations leads to an increased
cellular proliferation, invasion and motility and a decreased cell-cell (adherens junctions) and
cell-matrix adhesion (focal adhesions) (1). A significant number of the phosphopeptides
detected in our chemical rescue analysis are involved in cell adhesion and, in particular, in focal
adhesion pathways (Figure 7). c-Src is known to play a role in the regulation and disassembly of
focal adhesions, which link the extracellular matrix to the actin cytoskeleton (57) and are also
involved in signaling pathways that regulate proliferation and gene transcription (58). Our work
here provides a number of possible novel connections in this regard. A network map that
includes the role of c-Src in focal adhesions and highlights the novel proteins and
phosphopeptides identified in our study is shown in Figure 7.
Focal adhesions form when integrin connects the ECM to a complex of proteins that acts
as a link between integrins and the actin cytoskeleton. Several tyrosine sites from cytoskeletal
proteins that are part of this supramolecular structure and have not previously been described as
c-Src substrates experienced an increase in their phosphorylation level include talin (Tyr436),
filamin B (Tyr2502), tensin 1 (Tyr1477, Tyr1480, Tyr1558), and tensin2 (Tyr483, Tyr705,
New c-Src targets revealed by chemical rescue and proteomics
29
Tyr770, Tyr770). Tensin 3 is a recently discovered c-Src target (59) but the site found in this
study, Tyr584, has never shown to be phosphorylated by c-Src.
The activation of RhoA is one of the key events of focal-adhesion assembly (60). c-Src
blocks downstream signalling by RhoA through activation of p190 RhoGAP, leading to focal-
adhesion disruption and increased motility (61). Two other RhoGAPs are known to be
phosphorylated by c-Src: RhoGAP3 (Tyr21-known (60)), and RhoGAP5 (63) (Tyr342-known,
749-known). Interestingly, we detected two other RhoGAPs that have never been described as c-
Src substrates: RhoGAP42 (Tyr342-unknown; Tyr759-unknown) and RhoGAP32 (Tyr2025-
unknown).
It is known that c-Src phosphorylates and activates Fak at sites Tyr614 and Tyr615
promoting maximal Fak catalytic activity (64). Interestingly we detected a new Fak
phosphorylation site, Tyr5, which underwent a c-Src mediated increase in phosphorylation and
has never been identified as a c-Src substrate. Similarly, p130Cas is a well-known substrate of
active Fak-Src. Several known sites and a new phosphorylation site, Tyr331, showed an
increased phosphorylation level upon c-Src rescue.
The Rap1 guanine exchange factor (C3G) was also detected in our proteomic studies and
plays a role in focal adhesion signaling as indicated in Figure 7. The temporal connection
between c-Src and C3G identified here allow us to propose a molecular mechanistic pathway for
Rap1 control. It has been shown that Crk is constitutively associated with C3G (65). We show
that rapid activation of c-Src enhances interaction between C3G and Crk by 1 minute. Such
regulation of this complex may account for reported responses after the stimulation of cells by
insulin, integrin engagement, and other natural triggers (66-68). Presumably, the adaptor protein
Crk drives C3G to the cell periphery, where we detected it within minutes after c-Src rescue.
New c-Src targets revealed by chemical rescue and proteomics
30
Increased phosphorylation of C3G on Tyr514 is known to facilitate C3G’s activity to catalyze
GTP exchange on Rap1 (38), consistent with our live cell reporter assay, which showed a
maximum level of activity at 5 minutes. Interestingly, the binding between C3G and Crk shows
a decrease at this time, possibly initiating retrograde signaling in this pathway (66).
We showed that the level of phosphorylation of Crk on Tyr221 increases upon c-Src
activation. Interestingly the observed decrease in Crk-C3G binding occurs when
phosphorylation of Crk on Tyr221 reaches a maximum level. Subsequently, Rap1 activation
appears to be indirectly modulated downward in a fashion that is correlated with Crk
phosphorylation on residue Tyr221. Phosphorylation of Crk on Tyr221 and the consequent
dissociation of the C3G-Crk complex at 5 minutes might contribute to the decrease in Rap1
activity that follows. Abl kinase has been identified as Crk upstream kinase on Tyr 221 (47). In
this regard, our phosphopeptide mapping revealed that sites Tyr439 of Abl/Arg, which has
additive effects on Abl activation (69) and has not been described previously as a c-Src substrate,
increased phosphorylation level significantly 5 minutes after c-Src chemical rescue. It is also
noteworthy that rescue induced an ~3-fold increase in phosphorylation of a new site, Tyr571
(Supplementary Figure 7), on C3G that may also modulate C3G’s ability to activate Rap1.
However, we caution that the exact timing of each event: C3G phosphorylation, C3G-Crk
binding, C3G translocation to the membrane, and Rap1 activation cannot be revealed with
certainty because of the varying techniques and limited temporal resolution associated with these
methods. This may account for the slight delay in Rap1 activity decrease relative to Crk-C3G
binding disruption and C3G phosphorylation.
In summary, the chemical rescue approach has allowed a kinetic description of c-Src
signaling events that would otherwise have been difficult to obtain. In principle, this technique
New c-Src targets revealed by chemical rescue and proteomics
31
can be applied to other non-receptor PTKs to provide a more complete portrait of tyrosine
phosphorylation networks in cell signaling.
References
1. Yeatman, T. J. (2004) A renaissance for Src. Nature Rev. Cancer 4, 470-480
2. Shah, K., and Shokat, K (2002) A chemical genetic screen for direct v-Src substrates reveals
ordered assembly of a retrograde signalling pathway. Chem. Biol 9, 35-47
3. Qiao, Y., Molina, H., Pandey, A., Zhang, J., and Cole, P.A. (2006) Chemical rescue of a
mutant enzyme in living cells. Science 311, 1293–1297
4. Amanchy, R., Zhong, J., Molina, H., Chaerkady, R., Iwahori, A., Kalume, D.E., Gronborg,
M., Joore, J., Cope, L., and Pandey, A. (2008) Identification of c-Src tyrosine kinase substrates
using mass spectrometry and peptide microarrays. J. Proteome Res 7, 3900–3910
5. Luo, W., Slebos, R.J., Hill, S., Li, M., Brabek, J., Amanchy, R., Chaerkady, R., Pandey, A.,
Ham, A.J., and Hanks, S.K. (2008) Global impact of oncogenic Src on a phosphotyrosine
proteome. J. Proteome Res 7, 3447–3460
6. Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Donald J.
Fujita, D.J., Jove, R. and Yeatman, T.J. (1999) Activating SRC mutation in a subset of advanced
human colon cancers. Nature Genetics 21, 187 - 190
New c-Src targets revealed by chemical rescue and proteomics
32
7. Amanchy, R., Zhong, J., Hong, R., Kim, J.H., Gucek, M., Cole, R.N., Molina, H., and Pandey,
A. (2009) Identification of c-Src tyrosine kinase substrates in platelet-derived growth factor
receptor signaling. Mol. Oncol 3 (5-6), 439-450
8. Bishop, A.C., Ubersax, J.A., Petsch, D.T., Matheos, D.P., Gray, N.S., Blethrow, J., Shimizu,
E., Tsien, J.Z., Schultz, P.G., Rose, M.D., Wood, J.L., Morgan, D.O., and Shokat, K.M. (2000) A
chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407 (6802), 395-401
9. Pratt, M.R., Schwartz, E.C., Muir, T.W. (2007) Small-molecule- mediated rescue of protein
function by an inducible proteolytic shunt. Proc. Natl. Acad. Sci. U S A 104 (27), 11209-14
10. Karginov, A.V., Ding, F., Kota, P., Dokholyan, N.V., and Hahn, K.M. (2010) Engineered
allosteric activation of kinases in living cells. Nat. Biotechnol. 28(7), 743-7
11. Dephoure, N., Howson, R.W., Blethrow, J.D., Shokat, K.M., and O'Shea, E.K. (2005)
Combining chemical genetics and proteomics to identify protein kinase substrates. Proc. Natl.
Acad. Sci. USA 102, 17940-17945
12. Williams, D.M., Wang, D., and Cole, P.A. (2000). Chemical rescue of a mutant protein-
tyrosine kinase. J. Biol. Chem. 275(49), 38127-30
New c-Src targets revealed by chemical rescue and proteomics
33
13. Lowry, W.E., Huang, J., Ma, Y.C., Ali, S., Wang, D., Williams, D.M., Okada, M., Cole,
P.A., and Huang, X.Y. (2002) Csk, a critical link of G protein signals to actin cytoskeletal
reorganization. Dev. Cell 2, 733-744
14. Muratore, K.E., Seeliger, M.A., Wang, Z., Fomina, D., Neiswinger, J., Havranek, J.J., Baker,
D., Kuriyan, J., and Cole, P.A. (2009) Comparative analysis of mutant tyrosine kinase chemical
rescue. Biochemistry 48, 3378-3386
15. Rush, J., Moritz, A., Lee, K.A., Guo, A., Goss, V.L., Spek, E.J., Zhang, H., Zha, X.M.,
Polakiewicz, R.D., and Com, M.J. (2005) Immunoaffinity profiling of tyrosine phosphorylation
in cancer cells. Nat. Biotechnol. 23, 94-101
16. Harsha, H.C., Molina, H., and Pandey, A. (2008) Quantitative proteomics using stable
isotope labeling with amino acids in cell culture. Nat. Protoc. 3(3), 505-516
17. Rappsilber, J., Mann, M., and Ishihama, Y. (2007) Protocol for micro-purification, pre-
fractionation and storage of peptides using StageTips. Nat. Protoc. 2, 1896-1906
18. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R.A., Olsen, J.V., and Mann, M. (2011)
Andromeda: a peptide search Enghien integrated into the MaxQuant environment. J. Proteome
Res 10, 1794-1805
New c-Src targets revealed by chemical rescue and proteomics
34
19. Perkins, D.N., Pappin, D.J., Creasy, D.M., and Cottrell, J.S. (1999) Probability-based proteín
identification by searching sequence databases using mass spectrometry data. Electrophoresis
20, 3551-3567
20. Eng, J.K., Mccormack, A.L., and Yates, J. R. (1994) An approach to correlate tandem mass-
spectral dataof peptides with amino-acid-sequences in a proteína database. Journal of the
American Society for Mass Spectrometry 5, 976-989
21. Balgley, B.M., Laudeman, T., Yang L., Song T., and Lee C.S. (2007) Comparative
evaluation of tandem MS search algorithms using a target-decoy search strategy. Mol. Cell.
Proteomics 6,1599-1608
22. Peri, S., Navarro, J.D., Amanchy, R., Kristiansen, T.Z., Jonnalagadda, C.K.,Surendranath,
V., Niranjan, V., Muthusamy, B., Gandhi, T.K., Gronborg, M., Ibarrola, N., Deshpande, N.,
Shanker, K., Shivashankar, H.N., Rashmi, B.P., Ramya, M.A., Zhao, Z., Chandrika, K.N.,
Padma, N., Harsha, H.C., Yatish, A.J., Kavitha, M.P., Menezes, M., Choudhury, D.R., Suresh,
S., Ghosh, N., Saravana, R., Chandran, S., Krishna, S., Joy, M., Anand, S.K., Madavan, V.,
Joseph, A., Wong, G.W., Schiemann, W.P., Constantinescu, S.N., Huang, L., Khosravi-Far, R.,
Steen, H., Tewari, M., Ghaffari, S., Blobe, G.C., Dang, C.V., Garcia, J.G., Pevsner, J., Jensen,
O.N., Roepstorff, P., Deshpande, K.S., Chinnaiyan, A.M., Hamosh, A., Chakravarti, A., and
Pandey, A. (2003) Development of human protein reference database as an initial platform for
approaching systems biology in humans. Genome Research 13, 2363-2371
New c-Src targets revealed by chemical rescue and proteomics
35
23. Dennis, G., Jr., Sherman, B.T., Hosacl, D.A., Yang, J., Gao, W., Lane, H.C., Lempicki, R.A.
(2003) DAVID: Database for Annotation, Visualization and Integrated Discovery. Genome Biol
4, P3
24. Mochizuki, N., Yamashita, S., Kurokawa, K., Ohba, Y., Nagai, T., Miyawaki, A., and
Matsuda, M. (2001) Spatio-temporal images of growth-factor-induced activation of Ras and
Rap1. Nature 411,1065 -1068
25. Klinghoffer, R.A., Sachsenmaier, C., Cooper, J.A., and Soriano, P. (1999) Src family kinases
are required for integrin but not PDGFR signal transduction. EMBO J. 18, 2459-71
26. Ong, S.E., and Mann, M. (2006) A practical recipe for stable isotope labeling by aminoacids
in cell culture (SILAC). Nat. Protoc. 1, 2650-2660
27. Hornbeck, P.V., Chabra, I., Kornhauser, J.M., Skrzypek, E., and Zhang, B. (2004)
PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation.
Proteomics 4, 1551-61
28. Wei, J., Xu, G., Zhang, Y., Li, Q., Liu, P., Zhu, T., Song, A., Zhao, L., Han, Z., Chen, G.,
Wang, S., Meng, L., Zhou, J., Lu, Y., Wang, S., and Ma, D. (2008) Overexpression of vimentin
contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res. 28,
327-334
New c-Src targets revealed by chemical rescue and proteomics
36
29. Cussac, D., Greenland, C., Roche, S., Bai, R.Y., Duyster, J., Morris, S.W., Delsol, G.,
Allouche, M., Payrastre, B. (2004) Nucleophosmin-anaplastic lymphoma kinase of anaplastic
large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood
103, 1464-1471
30. Olsen, J.V., de Godoy, L.M., Li, G., Macek, B., Mortensen, P., Pesch, R., Makarov, A.,
Lange, O., Horning, S., and Mann, M. (2005) Parts per million mass accuracy on an Orbitrap
mass spectrometer via lock mass injection into a C-trap. Mol. Cell. Proteomics 4, 2010–2021
31. Carragher, N.O., Westhoff, M.A., Fincham, V.J., Schaller, M.D., and Frame, M.C. (2003) A
novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and Src. Curr
Biol 13: 1442–1450
32.Hynes, R.O. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69:
11–25
33. Voss, A.K., Gruss, P., and Thomas, T. (2003) The guanine nucleotide exchange factor C3G
is necessary for the formation of focal adhesions and vascular maturation. Development 130,
355-367
34. Tanaka, S., Morichita, T., Hashimoto, Y., Hattori, S., Nakamura, S., Shibuya, M., Matuoka,
K., Takenawa, T., Kurata, T., Nagashima, K., and Matsuda, M. (1994) C3G, a guanine
New c-Src targets revealed by chemical rescue and proteomics
37
nucleotide releasing protein expressed ubiquitously binds to SH3 domain of CRK and GRB2/
ASH proteins. Proc. Natl. Acad. Sci. USA 91, 3443-3447
35. Knudsen, B.S., Feller, S.M., and Hanafusa, H. (1994) Four proline rich sequences of the
guanine nucleotide exchange factor C3G bind with unique specificity to the first SH3 domain of
Crk. J. Biol. Chem. 269, 32781-32787
36. Gotoh, T., Hattori, S., Nakamura, S., Kitayama, H., Noda, M., Takai, Y., Kaibuchi, K.,
Matsui, H., Hatase, O., and Takahashi, H. (1995) Identification of Rap1 as a target for the Crk
SH3 domain-binding GNRF-C3G. Mol. Cell. Biol 15, 6746-6753
37. Ohba, Y., Mochizuki, N., Matsuo, K., Yamashita, S., Nakama, M., Hashimoto, Y.,
Hamaguchi, M., Kurata, T., Nagashima, K., and Matsuda, M. (2000) Rap2 as a slowly
responding molecular switch in the Rap1 signaling cascade. Mol. Cell. Bio.l 20, 6074-6083
38. Ichiba, T., Hashimoto, Y., Nakaya, M., Kuraishi, Y., Tanaka, S., Kurata, T, Mochizuki, N.,
and Matsuda, M. (1999) Activation of C3G guanine nucleotide exchange factor for Rap1 by
phosphorylation of tyrosine 504. J. Biol. Chem. 274, 14376-14381
39. Radha, V., Rajanna, A., and Swarup, G. (2004) Phosphorylated guanine nucleotide Exchange
factor C3G, induced by pervanadate and Src family kinases localizes to the Golgi and subcortical
actin cytoskeleton. BMC Cell. Biol. 4, 31
New c-Src targets revealed by chemical rescue and proteomics
38
40. Matsuda, M., Tanaka, S., Nagata, S., Kojima, A., Kurata, T., and Shibuya, M. (1992) Two
species of human CRK cDNA encode proteins with distinct biological activities. Mol. Cell. Biol.
12, 3482-3489
41. Xing, L., Ge, C., Zeltser, R., Maskevitch, G., Mayer, B.J., and Alexandropoulos, K. (2000) c-
Src signaling induced by the adapters Sin and Cas is mediated by Rap1 GTPase. Mol. Cell. Biol.
20, 7363-7377
42. Kiyokawa, E., Mochizuki, N., Kurata, T., and Matsuda, M. (1997) Role of Crk oncogene
product in physiologic signaling. Crit. Rev. Oncog. 8, 329–342
43. Zhu, T., Goh, E.L., LeRoith, D., and Lobie, P.E. (1998) Growth hormone stimulates the
formation of a multiprotein signaling complex involving p130(Cas) and CrkII. Resultant
activation of c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK). J. Biol. Chem
273, 33864-33875
44. Ling, L., Zhu, T., and Lobie, P.E. (2003) Src-CrkII-C3G-dependent Activation of Rap1
Switches Growth Hormone-stimulated p44/42 MAP Kinase and JNK/SAPK Activities. J. Biol.
Chem. 278, 27301-27311
45. Knudsen, B.S., Zheng, J., Feller, S.M., Mayer, J.P., Burrell, S.K., Cowburn, D., and
Hanafusa, H. (1995) Affinity and specifity requirements for the first Src homology 3 domain of
the Crk proteins. EMBO J. 14, 2191-2198
New c-Src targets revealed by chemical rescue and proteomics
39
46. Feller, S.M., Knudsen, B., and Hanafusa, H. (1994) c-Abl kinase regulates the protein
binding activity of c-Crk. EMBO J. 13, 2341-2351
47. Hashimoto,Y., Katayama, H., Kiyokawa, E., Ota, S., Kurata, T., Gotoh, N., Shibata, M.,
Otsuka, N., and Matsuda, M. (1998) Phosphorylation of CrkII adaptor protein at tyrosine 221 by
epidermal growth factor receptor J. Biol. Chem. 273, 171186- 17191
48. Rosen, M.K., Yamazaki, T., Gish, G.D., Kay, C.M., Pawson, T., and Kay, L.E. (1995) Direct
demonstration of an intramolecular SH2-phosphotyrosine interaction in the Crk protein. Nature
374 (6521), 477-479
49. Bos, J.L. (1998) All in the family? New insights and questions regarding interconnectivity of
Ras, Rap1 and Ral. EMBO J. 17, 6776-6782
50. Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y., and Noda, M. (1989) A ras-related
gene with transformation suppressor activity. Cell 56, 77-84
51. Cook, S.J., Rubinfeld, B., Albert, I., and McCormick, F. (1993) RapV12 antagonizes Ras-
dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts. EMBO J. 12,
3475-3485
New c-Src targets revealed by chemical rescue and proteomics
40
52. Bos, J.L., de Rooij, J., Reedquist, K.A. (2001) Rap1 signalling: adhering to new models. Nat.
Rev. Mol. Cell. Biol. 2, 369-377
53. Madhusoodanan, K.S., Guo, D., McGarrigle, D.K., Maack, T., Huang, X.Y. (2006) Csk
mediates G-protein-coupled lysophosphatidic acid receptor-induced inhibition of membrane-
bound guanylyl cyclase activity. Biochemistry 45, 3396-3403.;
54. Im, E.; Kazlauskas, A. (2007) Src family kinases promote vessel stability by antagonizing the
Rho/ROCK pathway. J. Biol. Chem. 282, 29122-29129
55. Lu, W., Gong, D., Bar-Sagi, D., Cole, P.A. (2001) Site-specific incorporation of a
phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling.
Mol. Cell 8(4), 759-769
56. Zhang, Z., Shen, K., Lu, W., and Cole, P.A. (2003) The role of C-terminal tyrosine
phosphorylation in the regulation of SHP-1 explored via expressed protein ligation. J. Biol.
Chem 278, 4668-74.
57. Sastry, S.K., and Burridge, K. (2000) Focal adhesions: a nexus for intracellular signaling and
cytoskeletal dynamics. Exp. Cell. Res. 261, 25–36
58. Jamora, C., and Fuchs, E. (2002) Intercellular adhesion, signalling and the cytoskeleton.
Nature Cell Biol. 4, E101–E108
New c-Src targets revealed by chemical rescue and proteomics
41
59. Qian, X., Li, G., Vass, W.C., Papageorge, A., Walker, R.C., Asnaghi, L., Steinbach, P.J.,
Tosato, G., Hunker, K., and Lowy, D.R. (2009) The Tensin-3 protein, including its SH2 domain,
is phosphorylated by Src and contributes to tumorigenesis and metastasis. Cancer Cell 16(3),
246-258
60. Fujisawa, K., Madaule, P., Ishizaki, T., Watanabe, G., Bito, H., Saito, Y., Hall, A., and
Narumiya, S. (1998) Different regions of Rho determine Rho-selective binding of different
classes of Rho target molecules. J. Biol. Chem. 273, 18943–18949
61. Chang, J.H., Gill, S., Settleman, J., and Parsons, S.J. (1995) c-Src regulates the simultaneous
rearrangement of actin cytoskeleton, p190RhoGAP, and p120RasGAP following epidermal
growth factor stimulation. J. Cell. Biol. 130, 355–368
62. Kai, M., Yasuda, S., Imai, S., Kanoh, H., and Sakane, F. (2007) Tyrosine phosphorylation of
beta2-chimaerin by Src-family kinase negatively regulates its Rac-specific GAP activity.
Biochim. Biophys. Acta 1773, 1407-1415
63. Zrihan-Licht, S., Fu, Y., Settleman, J., Schinkmann, K., Shaw, L., Keydar, I., Avraham, S.,
and Avraham, H. (2000) RAFTK/Pyk2 tyrosine kinase mediates the association of p190
RhoGAP with RasGAP and is involved in breast cancer cell invasion. Oncogene 19, 1318-1328
64. Mitra, S.K., Hanson, D.A., and Schlaepfer, D.D. (2005) Focal adhesion kinase: in command
New c-Src targets revealed by chemical rescue and proteomics
42
and control of cell motility. Nature Reviews Molecular Cell Biology 6, 56-68
65. Zhu, T., Goh, E.L., and Lobie, P.E. (1998) Growth hormone stimulates the tyrosine
phosphorylation and association of p125 focal adhesion kinase (FAK) with JAK2. Fak is not
required for stat-mediated transcription. J. Biol. Chem. 273, 10682- 10689
66. Okada, S., and Pessin, J.E. (1997) Insulin and epidermal growth factor stimulate a
conformational change in Rap1 and dissociation of the CrkII-C3G complex. J. Biol. Chem. 272,
28179-82
67. Okada, S., Matsuda, M., Anafi, M., Pawson, T., and Pessin, J.E. (1998) Insulin regulates the
dynamic balance between Ras and Rap1 signaling by coordinating the assembly states of the
Grb2-SOS and CrkII-C3G complexes. EMBO J. 17, 2554-2565
68. Buensuceso, C.S., and O’Toole, T.E. (2000) The association of CRKII with C3G can be
regulated by integrins and defines a novel means to regulate the mitogen-activated protein
kinase. J. Biol. Chem. 275, 13118-13125.
69. Tanis, K.Q., Veach, D., Duewel, H.S., Bornmann, W.G., and Koleske, A.J . (2003) Two
distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol.
Cell. Biol. 23, 3884-3896
New c-Src targets revealed by chemical rescue and proteomics
43
Acknowledgments
We thank the NIH for financial support. Isabel Martinez- Ferrando is a recipient of a Fulbright
Graduate Scholarship from the International Institute of Education- Fulbright Spain, Government
of Spain. We thank Dr. Michiyuki Matsuda for providing us with the Raichu-Rap1 FRET
Reporter. We thank Barbara Smith and Michael Delannoy from the Microscope Facility at the
Johns Hopkins School of Medicine for their assistance. We thank Bob Cotter and Bob O’Meally
from the Mass Spectrometry and Proteomics Facility for help.
Footnotes
The raw data associated with this manuscript may be downloaded from ProteomeCommons.org
Tranche, http://proteomecommons.org/tranche/, using the following hash:
TzGvo1FbhJkLaM/FDLKTewGrBYDqWRPO/Oe9KHmXiohZonXBuLlolUe2NuY4G/UIubBh
NQjySdOasclB3Os1vYmje8gAAAAAAAAJtw==
This article contains the following supplementary data: Supplementary Table 1, a complete list
of tyrosine phosphorylated proteins quantitated by SILAC. Supplementary Table 2, a complete
list of tyrosine phosphorylated peptides quantitated by SILAC. Supplementary Table 3, a list of
c-Src induced,upregulated phosphorylated peptides, Supplementary Table 4, a list of putative Src
substrates from references 3-5,7. Supplementary Table A, a list of phosphoPSM identified by
Mascot and SEQUEST. Supplementary Table B, a list of phosphoPSM identified by MaxQuant.
New c-Src targets revealed by chemical rescue and proteomics
44
Supplementary Figure 1, Quality control studies of proteomics samples used for
phosphotyrosine-site mapping. Supplementary Figure 2, Flow-chart representing the complete
data analysis process corresponding to the phosphopeptide enrichment by SILAC and LC-
MS/MS. Supplementary Figure 3, Optimization of c-Src rescue conditions. Supplementary
Figure 4, Anti-pTyr western blot with imidazole treatment of SYF and WT MEF cells.
Supplementary Figure 5, Validation of protein phosphorylation of known Src substrates Fak and
paxillin. Supplementary Figure 6, C3G and pTyr514-C3G increased localization at the cell
periphery after c-Src rescue. Supplementary Figure 7, Mass spectrum (MS) and tandem mass
spectrum (MS/ MS) of phosphopeptide from Rap Guanine Exchange Factor 1 (C3G).
Conflict of Interest: The authors declare no conflict of interest.
Figure Legends
Figure 1. c-Src chemical rescue by imidazole. (A) Proposed R390A c-Src chemical rescue
mechanism by imidazole indicating interactions of imidazole with the catalytic base Asp388 and
Tyr from the substrate (Based on PDB 3GEQ). (B) Comparison of the phosphotyrosine profile
of imidazole-treated cells compared to that of untreated cells. Tyrosine phosphorylation induced
by imidazole treatment (10 mM, 5 minutes) of SYF cells stably transfected with c-Src R390A
and D388N SYF (negative control). Cells were subjected to lysis and whole lysates were
subjected to Western blotting with 4G10 anti- phosphotyrosine antibody.
Figure 2. Scheme of the experimental design of SILAC-based quantitative
phosphoproteomic approach. SYF MEF cells stably transfected with R390A c-Src were
New c-Src targets revealed by chemical rescue and proteomics
45
divided into two populations that were grown in ‘light’ or ‘heavy’ medium. The population of
cells cultured in ‘heavy’ medium was treated with 10 mM imidazole for 5 minutes and the one
cultured in ‘light’ media was left untreated. Cell lysates were combined in equal proportions. (A)
The protein mixture was incubated with anti-phosphotyrosine antibodies for enrichment of
tyrosine- phosphorylated proteins. The enriched fraction was subjected to in-gel trypsinization.
(B) The protein mixture was first digested with trypsin and then incubated with anti-
phosphotyrosine antibodies for enrichment of tyrosine- phosphorylated peptides. In both cases,
the enriched samples were analyzed by LC- MS/MS.
Figure 3. Distribution of identified and quantified phosphoproteins. (A) Summary of fold
change in phosphorylation upon c-Src chemical rescue for all proteins in R390A c-Src SYF MEF
cells. Known Src protein substrates are indicated. Proteins with a heavy to light (H/L) ratio > 1.2
(red) increased their tyrosine phosphorylation level, and those with H/L ratio < 0.8 (green)
decreased their tyrosine phosphorylation level. Proteins that showed no significant change in
their tyrosine phosphorylation level (0.8 < H/L ratio < 1.2) are indicated in gray. The pie chart
indicates the distribution of proteins with either up regulated (H/L >1.2), constant (0.8 < H/L <
1.2) or down-regulated (H/L <0.8) tyrosine phosphorylation levels. (B) Functional distribution
of identified proteins with increased tyrosine phosphorylation level upon c-Src rescue.
Figure 4. Validation of protein phosphorylation by immunoprecipitation- immunoblot
analysis of R390A and D388N c-Src SYF cells after treatment with 10 mM for 5 min.
Immunoprecipitation was carried out with commercially available antibodies corresponding to
the protein of interest and immunoblotting was carried out with the 4G10 pTyr- antibody as well
New c-Src targets revealed by chemical rescue and proteomics
46
as protein-specific antibodies. Vimentin, C3G, tensin, matrin, nucleophosmin and GSK-3β are
some novel potential direct c-Src substrates, which were validated by immunoprecipitation-
immunoblot analysis.
Figure 5. Overview of identified phosphopeptides with upregulated tyrosine
phosphorylation upon c-Src rescue in R390A c-Src SYF MEF cells. All the detected
upregulated phosphopeptides are shown whether they are novel (red) or known (red and black
dot) c-Src substrate sites. As shown, the corresponding proteins span a wide variety of cellular
functions, such as polarity, actin remodeling, adaptors, kinases, phosphatases, GEF/GAP proteins
and are modulated by tyrosine phosphorylation following c-Src activation.
Figure 6. Ingenuity Pathway analysis of the c-Src upregulated phosphoproteome. (A)
Enrichment plots of ontology (x-axis) built on the list of 52 c-Src upregulated phosphoproteins.
The y-axis represents the significance of the enrichment, which was calculated using the
Benjiamini-Hochberg multiple testing correction, as –log10 of P-values. (B) Enrichment plots of
canonical pathways (x-axis) built on the list of 59 c-Src upregulated phosphoproteins. The right
y-axis (line) represents the percentage enrichment (ratio between the number of c-Src
upregulated proteins and the total number of proteins included in the pathway). The left y-axis
(bars) represents the significance of the enrichment, which was calculated using the Benjiamini-
Hochberg multiple testing correction, as –log10 of P-values. From the complete list of pathways
obtained from the list of the c-Src upregulated phosphoproteins by Ingenuity Systems, the ones
with a value of -log (BH-P) ≥ 6 are represented.
New c-Src targets revealed by chemical rescue and proteomics
47
Figure 7. Role of c-Src in Focal Adhesion Signaling. The signaling pathways involved in
focal adhesion activation by integrins and the resulting downstream signaling events are
represented. The biological functions resulting from focal adhesions are also summarized. For
each of the proteins involved the sites that are known substrates of c-Src are indicated. The
modulation of phosphotyrosine sites that were identified in our experiment is indicated as
significantly increased (red), not modulated (gray), or decreased (blue). Among the identified
sites some are known c-Src substrates (black dot).
Figure 8. Spatio-temporal dissection of the activation mechanism for the identified c-Src
substrate, C3G. (A) Immunoprecipitation with anti-C3G antibody and western blot using anti
pTyr514-C3G antibody showed an increase in the phosphorylation level of tyrosine 514 in C3G
after 2.5 min that was sustained until 7.5 minutes upon c-Src rescue in R390A c-Src SYF cells
but not in D388N c-Src SYF cells. (B) Co-Immunoprecipitation using C3G
immunoprecipitation and Crk blotting showed an increase in C3G-Crk binding after 1 minute
upon imidazole treatment which was sustained until 2.5 minutes and decreased at minute 5 in
R390A c-Src SYF cells but not in D388N c-Src SYF cells. (C) Western blot using anti-pTyr221
in Crk showed a gradual increase in phosphorylation upon c-Src rescue reaching the highest level
of phosphorylation at minute 5 in R390A c-Src SYF cells but not in D388N c-Src SYF cells. The
maximum level of phosphorylation was reached at the same point at which C3G and Crk showed
a decreased binding. (D) R390A c-Src/SYF cells were treated with 10 mM imidazole and fixed
at various time points. Localization of both C3G and pTyr514-C3G was detected by staining
with C3G (Rhodamine) and pTyr514-C3G (FITC) and nuclei stained by DAPI. Images were
acquired by confocal microscopy. Representative images at 100x magnification are shown. Cells
New c-Src targets revealed by chemical rescue and proteomics
48
(n>40) were categorized according to phenotype (cytosolic vs peripheral) and quantified.
Quantitative analysis of C3G and pTyr514-C3G cellular localization was measured as a function
of imidazole treatment time. Images were captured by confocal microscopy at 40x magnification
as the ones shown in Supplementary Figure 6. Six representative images (at least 40 cells) were
quantified for each condition. Each cell was scored for whether it had peripheral staining. The
fraction of cells with peripheral staining was calculated for each image and averages were
calculated by combining the six images for each condition. Each time point was normalized to
time zero and standard errors are shown. Statistical significance (p<0.05) compared with time
zero was calculated using a Student’s T test and is indicated with an asterisk (*). (E) Rap1
activation upon c-Src rescue in R390A c-Src SYF cells (red) and D388N c-Src SYF cells (blue).
The FRET-based GTPase sensor, Raichu-Rap1 showed a 10% increase in FRET (Rap1
activation indicator) along the cell membrane after 8 min of treatment with imidazole to rescue
c-Src activity.
Figure 2 R390A c-Src SYF cells
12C-Arg, 12C-Lys media 13C-Arg, 13C-Lys media
IMIDAZOLE TREATMENT
“Light” Lysate “Heavy” Lysate
Combine lysates
Immunoafinity purification of pTyr-proteins
SDS- PAGE, in-gel trypsin digestion
Tyrosine phosphorylated PROTEIN identification
Tyrosine phosphorylated PEPTIDE identification
CONTROL (No treatment)
LC-MS/MS analysis
A B
Lysate trypsin digestion
Immunoaffinity purification of pTyr-peptides
0
0.5
1
1.5
2
2.5
3
3.5
Protein
Dok1
p130Cas
FAK
Paxillin
Arhgef7 Src
Fol
d C
hang
e
M
easu
red
Rat
io [H
eavy
/ Lig
ht]
B
32 % > 1.2
0.8 - 1.2
< 0.8
60 %
8 %
9 35
67
AFigure 3
H/L > 1.2 1.2 > H/L > 0.8 H/L < 0.8
1
2
3
4
5
Signaling Adhesion/ cytoskeleton
Metabolic/ Biosynthetic enzymes
RNA synthesis/ processing
Protein synthesis/ processing
13
9 3
6
4 37 %
26 %
9 %
17 % 11 %
Figure 4
Vimentin R390A D388N
imidazole - + - + IP: Vim WB: p-Tyr IP: Vim WB: Vim
C3G (Rap GEF1) R390A D388N
imidazole - + - + IP: C3G WB: p-Tyr IP: C3G WB: C3G
Tensin R390A D388N
imidazole - + - + IP: Tensin WB: p-Tyr IP: Tensin WB: Tensin
Nucleophosmin R390A D388N
imidazole - + - + IP: NPM WB: p-Tyr
IP: NPM WB: NPM
Matrin R390A D388N
imidazole - + - + IP: Matrin WB: p-Tyr IP: Matrin WB: Matrin
GSK3β R390A D388N
imidazole - + - + IP: GSK3β WB: p-Tyr IP: GSK3β WB: GSK3β
Figure 6
B
-log
(B-H
p-v
alue
)
Cel
lula
r Mov
emen
t
Cel
l Sig
nalin
g
Cel
lula
r Fun
ctio
n an
d M
aint
enan
ce
Am
ino
Aci
d M
etab
olis
m
Pos
t- Tr
ansl
atio
nal M
odifi
catio
n
Sm
all M
olec
ule
Bio
chem
istry
Cel
lula
r Gro
wth
and
Pro
lifer
atio
n
Cel
l-To-
Cel
l Sig
nalin
g an
d In
tera
ctio
n
Cel
lula
r Ass
embl
y an
d O
rgan
izat
ion
Cel
l Cyc
le
Cel
lula
r Com
prom
ise
Cel
lula
r Dev
elop
men
t
Free
Rad
ical
Sca
veng
ing
Mol
ecul
ar T
rans
port
Cel
l Dea
th
Gen
e E
xpre
ssio
n
Cel
lula
r Res
pons
es to
The
rape
utic
s
Car
bohy
drat
e M
etab
olis
m
Pro
tein
Syn
thes
is
DN
A R
eplic
atio
n, R
ecom
bina
tion,
and
R
epai
r
RN
A P
ost-
Tran
scrip
tiona
l Mod
ifica
tion
Dru
g M
etab
olis
m
Nuc
leic
Aci
d M
etab
olis
m
Vita
min
and
Min
eral
Met
abol
ism
A -lo
g (B
-H p
-val
ue)
Ratio
Inte
grin
Sig
nalin
g
FAK
Sig
nalin
g
Eph
rin R
ecep
tor S
ignl
aing
ER
K/M
AP
K S
igna
ling
HG
F S
igna
ling
Act
in C
ytos
kele
ton
Sig
nalin
g
Axo
nal G
uida
nce
Sig
nalin
g
PA
K S
igna
ling
IGF-
1 S
igna
ling
PTE
N S
igna
ling
Cho
lecy
stok
inin
/ Gas
trin-
med
iate
d S
igna
ling
PD
GF
Sig
nalin
g
Neu
regu
lin S
igna
ling
Fcy
Rec
epto
r-m
edia
ted
Pha
gocy
tosi
s in
Mac
roph
ages
and
Mon
ocyt
es
Ger
m C
ell-S
erto
li C
ell J
unnc
tion
Sig
nalin
g
Cel
l Mor
phol
ogy
Src Y343 (m) Y424 (m) Y444 (m) Y535 (m)
PI3K
Paxillin Y31 (m) Y40 (m) Y88 (m)
Y118 (m)
p130Cas Y132 (m) Y169 (m) Y183 (m) Y196 (m) Y238 (m) Y253 (m) Y271 (m) Y291 (m) Y310 (m) Y331 (m) Y391 (m) Y414 (m) Y668 (m)
Crk
p190RhoGAP 1087 (m) 1105 (m)
ArhGAP3 Y21 (m)
ArhGAP5 Y1089 (m) Y1107 (m) ArhGAP32 Y2025 (m) ArhGAP42 Y342 (m) Y759 (m)
C3G Y514(m) Y571(m)
Rap1
DOCK1
Rac
B-Raf
MEK1
JNK
Shc1 Y349(m) Y350(m) Y423(m)
Grb2 Y160(m) Sos Ha-Ras
Raf-1 Y340(m) Y341(m)
ERK1 Y205 (m)
ERK2 Y185 (m)
ELK1
PTEN
PIP2 PIP3
Vav1 Y174 (m)
Vav3 Y173 (m)
PAK
Talin Y436 (m)
Filamin B Y2502(m)
Actinin 1 Y193 (m)
Vinculin Y100 (m) Y692 (m) Y822 (m)
Y1065 (m)
α Actin
F Actin
Tensin 1 Y1477(m) Y1480(m) Y1558(m)
PDK1 Y9 (m)
Y373(m) Y376 (m)
Akt/PKB Y315 (m) Y326 (m)
GSK-3β Y216 (m)
β-Catenin Y86 (m)
Y489 (m) Y654 (m)
c-Jun
Cdc42
Caveolin Fyn
Csk
MAPK signaling pathway
Regulation of actin cytoskeleton
Wnt signaling pathway
Apoptosis Cell survival Bad Bcl-2
Cell proliferation
Cell motility
FA turnover
Filopodia Lamellipodia
formation Actin
polymerization Stress fiber/ FA
formation
RhoGEF4 Y94 (m)
RhoGEF10L Y152 (m)
RhoA ROCK2 Y722 (m)
PIP5K) Y644 (m)
MLC
mDial
Tensin 2 Y483 (m) Y705 (m) Y770 (m) Y791 (m)
Tensin 3 Y584 (m)
Y1168 (m) Y1201 (m) Y1251 (m)
FAK Y5 (m))
Y428 (m) Y438 (m) Y614 (m) Y615 (m) Y899 (m) Y963 (m)
Integrin
Up (H/L > 1.2) Down (H/L < 0.8) None (0.8 < H/L < 1.2) Known c-Src phospho-site
pY modulation of identified sites Interactions Activation Inhibition Phosphorylation upon c-Src activation (5min)
Figure 7